Gemcitabine (GEM) and Vindesine (VDS) in advanced non-small cell lung cancer (NSCLC): A phase II study in elderly or poor performance status patients

This publication has 24 references indexed in Scilit:

• Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non–Small-Cell Lung Cancer
  JAMA, 2004
• Gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma
  Cancer, 2000
• Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
  New England Journal of Medicine, 1999
• Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung Cancer
  JNCI Journal of the National Cancer Institute, 1999
• Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II study
  European Journal Of Cancer, 1997
• Randomized study of vinorelbine (VRB) versus vindesine (VDS) in previously untreated stage IIIB or IV non-small-cell lung cancer (NSCLC)
  Annals of Oncology, 1996
• Activity of gemcitabine in patients with non-small cell lung cancer: A multicentre, extended phase II study
  European Journal Of Cancer, 1996
• Prospective Evaluation of the Feasibility of Cisplatin‐based Chemotherapy for Elderly Lung Cancer Patients with Normal Organ Functions
  Japanese Journal of Cancer Research, 1995
• Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials
  BMJ, 1995
• Is there a role for vindesine in the treatment of non-small cell lung cancer?
  Investigational New Drugs, 1993